The Anaplasma phagocytophilum Antibodies IFA (Indirect Fluorescent Antibody) Titre (IgG) marker is a critical serological assay used in the diagnosis of Anaplasmosis, a tick-borne disease caused by the bacterium Anaplasma phagocytophilum. This test specifically measures the Immunoglobulin G (IgG) antibodies in the patient's serum that are directed against A. phagocytophilum. IgG antibodies are a type of antibody that the immune system produces more slowly in response to an infection but which persists long-term, indicating either past exposure or a chronic infection. In the IFA test, a patient's serum is exposed to antigen substrates derived from A. phagocytophilum, and the binding of specific IgG antibodies to these antigens is then visualized using a fluorescently-labeled secondary antibody. The titre, or concentration, of these antibodies is determined by serially diluting the serum and assessing the highest dilution at which antibodies can still be detected, providing a quantitative measure of the antibody levels. A high titre of Anaplasma phagocytophilum IgG antibodies typically indicates either a recent active infection or past exposure, as these antibodies can remain in the bloodstream for an extended period post-infection. The interpretation of the results should be made in the context of clinical symptoms, patient history, and other diagnostic findings, as IgG antibodies can persist long after the infection has resolved. This test is crucial for confirming exposure to Anaplasma phagocytophilum and aiding in the diagnosis of Anaplasmosis, especially in patients presenting with symptoms like fever, muscle aches, and fatigue, and with a history of tick exposure.
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.